By TREVOR VAN MIERLO Most of us know the story of the Model T – but what’s often overlooked is how it applies to other industries, especially digital health. Let’s revisit: In the early 1900s cars were custom built. You’d meet with a consultant, design the car, place your order, and wait for months for…
In Connecticut, construction workers in the Local 478 union who complete addiction treatment are connected with a recovery coach who checks in daily, attends recovery meetings with them, and helps them navigate the return to work for a year. In Pennsylvania, doctors applying for credentials at Geisinger hospitals are not required to answer intrusive questions…
LOS ANGELES — Inside a bright new building in the heart of Skid Row, homeless people hung out in a canopy-covered courtyard — some waiting to take a shower, do laundry, or get medication for addiction treatment. Others relaxed on shaded grass and charged their phones as an intake line for housing grew more crowded….
Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw two long-awaited IPOs as well as rising M&A activity, which are two signals of market maturity — but looming policy shifts may challenge long-term…
KalVista Pharmaceuticals’ Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring. The post KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease appeared first on MedCity…
AI doesn’t need to be a black box — and hospitals don’t need to invest based on blind faith. With the right structure, questions, and metrics in place, healthcare leaders can cut through the hype and make decisions that actually drive value. The post Hospitals Are Investing in AI — How Can They Evaluate ROI?…
Conventional wisdom holds that orphan drugs treat rare (by definition) and more severe diseases. Because they treat diseases with significant unmet needs, their health benefits per person are large. But are they really? Does conventional wisdom align with the evidence? To answer the question myself and colleagues at FTI Consulting, including co-author Marie Steele-Adjognon, conducted…
We’ve seen how transformative innovation can be when supported by focused investment. But if we want to continue advancing healthcare in meaningful ways, we must expand our lens and invest in the spaces that have been left behind. The post Breaking the Cycle: Unlocking the Untapped Opportunities in Healthcare Innovation appeared first on MedCity News.
The rapid advances in AI and smartphone technologies hold promise for many stakeholders in the healthcare system — providers, payers, pharmaceutical drugmakers and public health agencies — that need to understand what’s happening with the patient in real time. The post The Secret To Improved Population Health Management May Be In Our Pockets appeared first on…
The Trump administration’s healthcare policy changes from the gutting of medical research grants to changes on the CDC vaccine board were the focus of the discussion on the latest episode of the Debunked Podcast with MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch. The post Debunked Episode 17: Is…